$ELDN
Eledon Pharmaceuticals, Inc.

2021 Q1 Form 10-K Financial Statement

#000156459021016828 Filed on March 31, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 2019 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.350M $10.05M $970.0K
YoY Change 93.64% 65.84% -47.28%
% of Gross Profit
Research & Development $5.653M $6.131M $1.330M
YoY Change 243.02% -24.57% -51.46%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $0.00
YoY Change 0.0%
% of Gross Profit
Operating Expenses $9.005M $6.131M $2.300M
YoY Change 166.58% -61.8% -49.78%
Operating Profit -$9.005M
YoY Change 166.58%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $5.000K $79.00K $20.00K
YoY Change -83.33% 97.5%
Pretax Income -$9.000M -$23.22M -$4.140M
YoY Change 10.06% 44.99% -9.41%
Income Tax -$501.0K -$404.0K
% Of Pretax Income
Net Earnings -$8.499M -$22.81M -$4.140M
YoY Change 3.94% 42.48% -9.41%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$573.2K -$15.73M -$5.750M
COMMON SHARES
Basic Shares Outstanding 14.31M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $108.6M $114.2M $8.800M
YoY Change 820.34% 1197.73% -32.31%
Cash & Equivalents $108.6M $114.2M $8.791M
Short-Term Investments
Other Short-Term Assets $26.00K $1.300M $54.00K
YoY Change -59.38% 30.0% 50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $110.2M $115.6M $9.971M
YoY Change 754.58% 1056.0% -30.16%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $100.0K $5.000K
YoY Change -66.67% -66.67% -64.29%
Goodwill $48.65M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $400.0K $639.0K
YoY Change -47.55% -33.33% -26.47%
Total Long-Term Assets $81.46M $81.60M $960.0K
YoY Change 9834.02% 8966.67% -65.09%
TOTAL ASSETS
Total Short-Term Assets $110.2M $115.6M $9.971M
Total Long-Term Assets $81.46M $81.60M $960.0K
Total Assets $191.7M $197.2M $10.93M
YoY Change 1297.23% 1709.17% -35.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.500M $1.400M $329.0K
YoY Change 102.43% 366.67% -52.25%
Accrued Expenses $2.700M $1.100M $1.000M
YoY Change 145.45% 10.0% -44.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.206M $2.500M $1.322M
YoY Change 123.96% 92.31% -47.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $100.0K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $100.0K
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.206M $2.500M $1.322M
Total Long-Term Liabilities $0.00 $0.00 $100.0K
Total Liabilities $7.811M $6.600M $1.466M
YoY Change 290.55% 340.0% -42.15%
SHAREHOLDERS EQUITY
Retained Earnings -$88.89M -$57.58M
YoY Change 38.51%
Common Stock $272.8M $67.05M
YoY Change 19.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $183.9M $190.6M $9.465M
YoY Change
Total Liabilities & Shareholders Equity $191.7M $197.2M $10.93M
YoY Change 1299.14% 1709.17% -35.8%

Cashflow Statement

Concept 2021 Q1 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$8.499M -$22.81M -$4.140M
YoY Change 3.94% 42.48% -9.41%
Depreciation, Depletion And Amortization $0.00 $10.00K $0.00
YoY Change 0.0%
Cash From Operating Activities -$5.166M -$15.21M -$2.030M
YoY Change 135.14% 9.78% -39.4%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $11.04M
YoY Change
Cash From Investing Activities $11.04M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.000M
YoY Change -6.99%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -450.0K 109.6M 0.000
YoY Change -108.67% 1032.5%
NET CHANGE
Cash From Operating Activities -5.166M -15.21M -2.030M
Cash From Investing Activities 11.04M
Cash From Financing Activities -450.0K 109.6M 0.000
Net Change In Cash -5.616M 105.4M -2.030M
YoY Change -287.58% -2621.02% -39.4%
FREE CASH FLOW
Cash From Operating Activities -$5.166M -$15.21M -$2.030M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1180000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
9971000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
316000
CY2020Q4 us-gaap Goodwill
Goodwill
48648000
CY2020Q4 nvus In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
383000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
639000
CY2020Q4 us-gaap Assets
Assets
197185000
CY2019Q4 us-gaap Assets
Assets
10931000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1366000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
329000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
144000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
180000
CY2020Q4 nvus Accrued Severance Current
AccruedSeveranceCurrent
12000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
961000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
813000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8791000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2483000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1322000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4106000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
144000
CY2020Q4 us-gaap Liabilities
Liabilities
6589000
CY2019Q4 us-gaap Liabilities
Liabilities
1466000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
270974000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
67046000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80393000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57582000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
190596000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
9465000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
197185000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6131000
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14306614
CY2020Q2 dei Entity Public Float
EntityPublicFloat
7293179
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6056000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10052000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15160397
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10931000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-354000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
720408
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15160397
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
720408
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8128000
CY2020 us-gaap Restructuring Charges
RestructuringCharges
2282000
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1867000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
79000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
40000
CY2020 nvus Warrant Inducement Expense
WarrantInducementExpense
4829000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23215000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16011000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-404000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-22811000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.72
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-24.42
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1451432
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
655526
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8550000
CY2020 nvus Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5380000
CY2020 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
-3796
CY2020 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1194000
CY2020 nvus Cancellation Of Common Stock In Exchange For Preferred Stock Shares
CancellationOfCommonStockInExchangeForPreferredStockShares
3796
CY2020 nvus Cancellation Of Common Stock In Connection With Reverse Split Value
CancellationOfCommonStockInConnectionWithReverseSplitValue
-25000
CY2020 nvus Temporary Equity Stock Issued During Period Value Acquisitions
TemporaryEquityStockIssuedDuringPeriodValueAcquisitions
69723000
CY2020 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
95226000
CY2020 nvus Adjustments To Additional Paid In Capital Fair Value Of Options Assumed In Acquisition
AdjustmentsToAdditionalPaidInCapitalFairValueOfOptionsAssumedInAcquisition
2950000
CY2020 nvus Adjustments To Additional Paid In Capital Fair Value Of Warrants Assumed In Acquisition
AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantsAssumedInAcquisition
12944000
CY2020 nvus Warrants Issued During Period Inducement Expense
WarrantsIssuedDuringPeriodInducementExpense
4829000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3171000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
14492000
CY2019 nvus Share Issuance At Market Value
ShareIssuanceAtMarketValue
107000
CY2019 nvus Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
9569000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1308000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9000
CY2020 nvus Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
178000
CY2019 nvus Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
173000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3171000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1308000
CY2020 nvus Deferred Tax Liability
DeferredTaxLiability
404000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-39000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1392000
CY2020 nvus Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-180000
CY2019 nvus Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-165000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15212000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13857000
CY2020 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
11035000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11035000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9000000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9676000
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
95226000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
109581000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9676000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
105404000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5380000
CY2020 nvus Cash Paid For Cancellation Of Common Stock In Connection With Reverse Split
CashPaidForCancellationOfCommonStockInConnectionWithReverseSplit
25000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4181000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8791000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12972000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114195000
CY2020 nvus Conversion Of Series X1 Preferred Stock Into Common Stock
ConversionOfSeriesX1PreferredStockIntoCommonStock
13000
CY2020 nvus Issuance Of Common Stock In Acquisition
IssuanceOfCommonStockInAcquisition
1194000
CY2020 nvus Issuance Of Non Voting Convertible Preferred Stock In Acquisition
IssuanceOfNonVotingConvertiblePreferredStockInAcquisition
69723000
CY2020 nvus Fair Value Of Options Assumed In Acquisition
FairValueOfOptionsAssumedInAcquisition
2950000
CY2020 nvus Fair Value Of Warrants Assumed In Acquisition
FairValueOfWarrantsAssumedInAcquisition
12944000
CY2020 nvus Accrued Offering Costs
AccruedOfferingCosts
450000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to stock-based compensation, accruals for liabilities, <font style="color:#000000;">fair value of assets acquired and liabilities assumed in a business combination, impairment of long lived assets, including</font> goodwill, and other matters that affect the consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements. </p>
CY2020 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-eighteen
CY2020Q4 nvus Number Of Consecutive Trading Days Required To Regain Compliance
NumberOfConsecutiveTradingDaysRequiredToRegainCompliance
P10D
CY2020 nvus Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9200000
CY2020Q4 nvus Working Capital
WorkingCapital
113100000
CY2019Q3 nvus Closing Bid Price Per Nasdaq Listing Notification Letter
ClosingBidPricePerNASDAQListingNotificationLetter
1.00
CY2019Q3 nvus Consecutive Business Days For Closing Bid Price Of Common Stock
ConsecutiveBusinessDaysForClosingBidPriceOfCommonStock
P30D
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3959302
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
487275
CY2020 us-gaap Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.
CY2020Q4 nvus Income Tax Examination Likelihood Of Favorable Settlement
IncomeTaxExaminationLikelihoodOfFavorableSettlement
0.50
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1157000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
734000
CY2020Q4 nvus Prepaid Clinical Expense
PrepaidClinicalExpense
89000
CY2019Q4 nvus Prepaid Clinical Expense
PrepaidClinicalExpense
102000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
41000
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
45000
CY2020Q4 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
110000
CY2019Q4 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
245000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
38000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
54000
CY2020Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
31000
CY2019Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
40000
CY2020Q4 nvus Accrued Clinical Current
AccruedClinicalCurrent
258000
CY2019Q4 nvus Accrued Clinical Current
AccruedClinicalCurrent
437000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
130000
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
67000
CY2019Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
199000
CY2020Q4 nvus Accrued Financing Costs
AccruedFinancingCosts
450000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
146000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7000
CY2018Q4 us-gaap Goodwill Gross
GoodwillGross
1867000
CY2020Q4 us-gaap Goodwill Gross
GoodwillGross
48648000
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
207000
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
188000
CY2020Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
195000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
188000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9M
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0325
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
146000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
146000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
144000
CY2020Q4 nvus Lessee Short Term Operating Lease Liability Payments Due Next Twelve Months
LesseeShortTermOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
33000
CY2019 nvus Number Of Milestones Achieved
NumberOfMilestonesAchieved
0
CY2020 nvus Number Of Milestones Achieved
NumberOfMilestonesAchieved
0
CY2020Q4 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
548000
CY2020Q4 nvus Contingent Liability
ContingentLiability
0
CY2019Q4 nvus Contingent Liability
ContingentLiability
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
764000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-23408000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-16174000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
193000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
163000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-23215000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16011000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-404000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-404000
CY2019 nvus Effective Federal And State Income Tax Rate
EffectiveFederalAndStateIncomeTaxRate
0.21
CY2020 nvus Effective Federal And State Income Tax Rate
EffectiveFederalAndStateIncomeTaxRate
0.21
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4875000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3362000
CY2020 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
215000
CY2019 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
207000
CY2020 nvus Effective Income Tax Rate Reconciliation Change In Warrant Fair Market Value Amount
EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount
1014000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
252000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
141000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Impairment Losses
IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
392000
CY2020 nvus Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
627000
CY2019 nvus Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
4000
CY2020 nvus Effective Income Tax Rate Reconciliation Section Three Hundred And Eighty Two Limitation On Net Operating Losses And Credits
EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits
10562000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
89000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
38000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-7858000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2994000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5151000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9947000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
705000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
506000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
14000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
43000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
802000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
391000
CY2020Q4 nvus Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
1905000
CY2019Q4 nvus Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
116000
CY2020Q4 nvus Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
30000
CY2019Q4 nvus Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
68000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8607000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11071000
CY2020Q4 nvus Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
29000
CY2019Q4 nvus Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
66000
CY2020Q4 nvus Deferred Tax Liabilities In Process Research And Development
DeferredTaxLiabilitiesInProcessResearchAndDevelopment
6801000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6830000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
66000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5883000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11005000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
4106000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
548000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
328000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
233000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
214000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
531000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
6000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-5100000
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
392815
CY2020 nvus Class Of Warrant Or Right Number Of Warrants Or Rights Issued
ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued
402397
CY2020 nvus Class Of Warrant Or Right Number Of Warrants Or Rights Exercised
ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised
457390
CY2020 nvus Class Of Warrant Or Right Number Of Warrants Or Rights Cancelled Or Expired
ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired
0
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
337822
CY2020 nvus Number Of Stock Compensation Plans
NumberOfStockCompensationPlans
3
CY2020 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05555555555
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
49798
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
42244
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
639
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
91403
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2191462
CY2020 nvus Share Based Compensation Arrangement By Share Based Payment Award Options In Connection With Acquisition
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInConnectionWithAcquisition
1346398
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
7784
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3621479
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3621479
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
878033
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
233.45
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
28.87
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
79.38
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
139.96
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.15
CY2020 nvus Share Based Compensation Arrangement By Share Based Payment Award Options In Connection With Acquisition Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInConnectionWithAcquisitionWeightedAverageExercisePrice
7.58
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
586.16
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.63
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
15.21
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.00
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y10M24D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y2M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23938701000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
23938701000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6297510000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
17100000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.77
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.74
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.07
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.87
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.00
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.01
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.01
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.03
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020 us-gaap Payments For Restructuring
PaymentsForRestructuring
2270000
CY2020Q4 us-gaap Restructuring Reserve
RestructuringReserve
12000
CY2020 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
120000
CY2019 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
500000
CY2020 nvus Business Acquisitions Pro Forma Research And Development Expense
BusinessAcquisitionsProFormaResearchAndDevelopmentExpense
9489000
CY2019 nvus Business Acquisitions Pro Forma Research And Development Expense
BusinessAcquisitionsProFormaResearchAndDevelopmentExpense
11441000
CY2020 nvus Business Acquisition Pro Forma General And Administrative Expense
BusinessAcquisitionProFormaGeneralAndAdministrativeExpense
8317000
CY2019 nvus Business Acquisition Pro Forma General And Administrative Expense
BusinessAcquisitionProFormaGeneralAndAdministrativeExpense
7585000
CY2020 nvus Business Acquisitions Pro Forma Restructuring Expense
BusinessAcquisitionsProFormaRestructuringExpense
2282000
CY2019 nvus Business Acquisitions Pro Forma Goodwill Impairment
BusinessAcquisitionsProFormaGoodwillImpairment
1867000
CY2020 nvus Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
20088000
CY2019 nvus Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
20893000
CY2020 nvus Business Acquisition Pro Forma Operating Income Loss
BusinessAcquisitionProFormaOperatingIncomeLoss
-19968000
CY2019 nvus Business Acquisition Pro Forma Operating Income Loss
BusinessAcquisitionProFormaOperatingIncomeLoss
-20393000
CY2020 nvus Business Acquisition Pro Forma Other Nonoperating Income Expense
BusinessAcquisitionProFormaOtherNonoperatingIncomeExpense
79000
CY2019 nvus Business Acquisition Pro Forma Other Nonoperating Income Expense
BusinessAcquisitionProFormaOtherNonoperatingIncomeExpense
40000
CY2020 nvus Business Acquisition Pro Forma Warrant Inducement Expense
BusinessAcquisitionProFormaWarrantInducementExpense
4829000
CY2020 nvus Business Acquisition Pro Forma Income Loss Before Provision For Income Taxes
BusinessAcquisitionProFormaIncomeLossBeforeProvisionForIncomeTaxes
-24718000
CY2019 nvus Business Acquisition Pro Forma Income Loss Before Provision For Income Taxes
BusinessAcquisitionProFormaIncomeLossBeforeProvisionForIncomeTaxes
-20353000
CY2020 nvus Business Acquisition Pro Forma Income Tax Expense Benefit
BusinessAcquisitionProFormaIncomeTaxExpenseBenefit
-404000
CY2020 nvus Business Acquisition Pro Forma Net Income Loss And Other Comprehensive Income Loss
BusinessAcquisitionProFormaNetIncomeLossAndOtherComprehensiveIncomeLoss
-24314000
CY2019 nvus Business Acquisition Pro Forma Net Income Loss And Other Comprehensive Income Loss
BusinessAcquisitionProFormaNetIncomeLossAndOtherComprehensiveIncomeLoss
-20353000
CY2020 nvus Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-15.44
CY2019 nvus Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-24.49
CY2020 nvus Business Acquisition Pro Forma Weighted Average Number Of Shares Outstanding Basic And Diluted
BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted
1574657
CY2019 nvus Business Acquisition Pro Forma Weighted Average Number Of Shares Outstanding Basic And Diluted
BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted
831014

Files In Submission

Name View Source Status
0001564590-21-016828-index-headers.html Edgar Link pending
0001564590-21-016828-index.html Edgar Link pending
0001564590-21-016828.txt Edgar Link pending
0001564590-21-016828-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gj1idfvuehkw000001.jpg Edgar Link pending
gj1idfvuehkw000002.jpg Edgar Link pending
gj1idfvuehkw000003.jpg Edgar Link pending
gj1idfvuehkw000004.jpg Edgar Link pending
nvus-10k_20201231.htm Edgar Link pending
nvus-20201231.xml Edgar Link completed
nvus-20201231.xsd Edgar Link pending
nvus-20201231_cal.xml Edgar Link unprocessable
nvus-20201231_def.xml Edgar Link unprocessable
nvus-20201231_lab.xml Edgar Link unprocessable
nvus-20201231_pre.xml Edgar Link unprocessable
nvus-ex1010_316.htm Edgar Link pending
nvus-ex1011_319.htm Edgar Link pending
nvus-ex108_318.htm Edgar Link pending
nvus-ex109_317.htm Edgar Link pending
nvus-ex11_777.htm Edgar Link pending
nvus-ex231_110.htm Edgar Link pending
nvus-ex311_11.htm Edgar Link pending
nvus-ex312_6.htm Edgar Link pending
nvus-ex321_12.htm Edgar Link pending
nvus-ex322_8.htm Edgar Link pending
nvus-ex45_320.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending